Clinical Trials on Non Small Cell Lung Cancer (NSCLC)

Total 8012 results

Ludwig Institute for Cancer Research
Xcovery Holding Company, LLC; Cancer Research Institute, New York City; MedImmune...

Completed

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Carcinoma | NSCLC | Non-small Cell Lung Cancer

United States
GU Research Network, LLC

Withdrawn

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Completed

Osimertinib Study in Indian Patients

Non Small Cell Lung Cancer (NSCLC)

India
Takeda

Withdrawn

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Non-Small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
UNC Lineberger Comprehensive Cancer Center
Celgene

Completed

Single Arm on the Tolerability of Weekly Nab-paclitaxel

Non Small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Completed

A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients (KINDLE)

Non-small-cell Lung Cancer (NSCLC)

Mexico, Peru, Argentina, Taiwan, India, Thailand, Colombia, Uruguay, Chile, Dominican Republic
PharmaMar

Completed

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Non-Small Cell Lung Cancer (NSCLC)

United States
Dartmouth-Hitchcock Medical Center
Sanofi; Genentech, Inc.

Completed

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | NSCLC | Non-small Cell Lung Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China

Completed

A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

China
Pfizer

Completed

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (ARCHER 1042)

Non Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of
UNC Lineberger Comprehensive Cancer Center
Peregrine Pharmaceuticals

Completed

Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

Non Small Cell Lung Cancer (NSCLC)

United States
National Taiwan University Hospital

Completed

Selumetinib in Combination With Gefitinib in NSCLC Patients

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Astex Pharmaceuticals, Inc.

Completed

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Non-small Cell Lung Cancer(NSCLC)

United States, Korea, Republic of, Spain, France, Canada
Grupo de Investigación y Divulgación Oncológica

Unknown

Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer (NSCLC)

Spain
Stanford University
Eli Lilly and Company; Genentech, Inc.

Completed

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Yonsei University

Withdrawn

An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NSCLC (Non-Small Cell Lung Cancer)
Yonsei University

Completed

Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer (DATE)

Non Small Cell Lung Cancer (NSCLC)

Korea, Republic of
Merck KGaA, Darmstadt, Germany

Completed

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (FLEX)

Non Small Cell Lung Cancer (NSCLC)

Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
Jeffrey Clarke
Merck Sharp & Dohme LLC; Grid Therapeutics

Suspended

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Metastatic NSCLC | Recurrent Non Small Cell Lung Cancer

United States
University Hospital, Essen

Recruiting

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict)

NSCLC, Stage I | NSCLC Stage II | NSCLC, Stage IIIA

Belgium, Germany, Netherlands
Dr Joanne CHIU

Recruiting

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

ALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

Hong Kong
Second Affiliated Hospital, School of Medicine,...
Tongji Hospital; Qilu Hospital of Shandong University; First Hospital of China... and other collaborators

Recruiting

A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

Pembrolizumab | Non-small-lung-cell Cancer, NSCLC

China
Beijing Haidian Hospital
307 Hospital of PLA; Peking University People's Hospital; 309th Hospital of Chinese...

Recruiting

The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation

Non-small Cell Lung Cancer(NSCLC)

China
Johns Hopkins University
AstraZeneca

Enrolling by invitation

ROSE for Improved Molecular Marker Testing Via EBUS (ROSE/NoROSE)

Non-small Cell Lung Cancer (NSCLC)

United States
Albert Einstein College of Medicine
Montefiore Medical Center

Active, not recruiting

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial. (SPRINT)

Non-small Cell Lung Cancer, NSCLC

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Active, not recruiting

Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. (PEOPLE)

Non Small Cell Lung Cancer (NSCLC)

Italy
Abramson Cancer Center of the University of Pennsylvania

Terminated

Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy

Non-Small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
Sanofi

Active, not recruiting

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Spain, United States, Brazil, Chile, Czechia, France, Hungary, Israel
TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics

Recruiting

Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NSCLC | Metastatic Lung Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Metastatic Non-Small Cell Lung Cancer | KRAS G12C

United States, Australia
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Metastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung Cancer

China
The Affiliated Hospital of Qingdao University

Recruiting

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer (PILOT)

Non-small-cell Lung Cancer (NSCLC)

China
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)

United States
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, Czechia, Italy, Portugal, Hong Kong, Thailand, Singapore, Bulgaria, Turkey, Argentina, Belgium, G... and more
Takeda

Recruiting

A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY (ENTIRETY)

Non-small Cell Lung Cancer (NSCLC)

Poland
Takeda

Recruiting

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Japan
Swiss Group for Clinical Cancer Research

Recruiting

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

NSCLC | Non-small Cell Lung Cancer

Switzerland
Olivera Finn

Recruiting

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, United Kingdom, Australia, Belgium, Brazil, Canada, China, Portugal, Spain, France, Germany, Poland, Hong Kong, Israel, Thailand, Turkey, Japan, Austria, Hungary, Italy, Taiwan, Netherlands, Greece, New... and more
Swiss Group for Clinical Cancer Research

Completed

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

NSCLC Non-small Cell Lung Cancer

Switzerland
Daping Hospital and the Research Institute of Surgery...
Xinqiao Hospital of Chongqing; First Affiliated Hospital of Chongqing Medical...

Completed

PPIO-006 Primary Tumor Resection for IVa NSCLC

Non-small-cell Lung Cancer (NSCLC)

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Stand Up To Cancer; CellSight Technologies, Inc.

Terminated

PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

United States
Amgen

Terminated

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

United States, Austria, Australia
AstraZeneca

Completed

Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom (CODAK)

Non-Small Cell Lung Cancer NSCLC

United Kingdom
Hoffmann-La Roche

Completed

The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Non-Small Cell Lung Cancer (NSCLC)

Germany
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. (AdvanTIG-306)

Non-small Cell Lung Cancer (NSCLC)
Eisai Inc.

Completed

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Taiwan, Hong Kong, Spain, Poland, Singapore, Russian Federation, Italy, Australia, France, Germany, Japan, United Kingdom, Korea, Republic of
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC

Completed

Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer (NEOMUN)

Non-small Cell Lung Cancer (NSCLC)

Germany
Ludwig Institute for Cancer Research
Boehringer Ingelheim; MedImmune LLC; PharmaJet, Inc.; CureVac; Cancer Research Institute...

Completed

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NSCLC | Metastatic Non-small Cell Lung Cancer

United States

Clinical Trials on Non Small Cell Lung Cancer (NSCLC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations